Explore

Rapid ReadRapid Read
Acmopatide Shows Promise in Improving Metabolic Outcomes for Type 1 Diabetes Patients

Acmopatide Shows Promise in Improving Metabolic Outcomes for Type 1 Diabetes Patients

A new signal-based glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist, acmopatide, has demonstrated positive results in a phase 2 clinical trial for patients with type 1 diabetes who are also overweight or obese. According to Klara Klein, MD, and colleagues at the University of North Carolina at Chapel Hill, preclinical trials indicated that acmopatide improved glycemic control, reduced food intake, and promoted weight loss. The phase 2, double-blind trial involved 111 patients with type 1 diabetes and a BMI of at least 27 kg/m2. Participants were randomly assigned to receive one of three doses of acmopatide (1.8 mg, 4.1 mg, or 6.6 mg) or a placebo. The primary endpoint was the percent change from baseline in hemoglobin A1C (HbA1C) at week 16, with secondary endpoints including changes in body weight and insulin dose. The study found that acmopatide, particularly at the 4.1 mg and 6.6 mg doses, led to significant reductions in HbA1C and body weight, as well as...
USA TodayUSA Today
The mistake diabetes specialists see after people start GLP-1 meds

The mistake diabetes specialists see after people start GLP-1 meds

Experts say GLP-1 drugs are just one part of diabetes care. Adding a continuous glucose monitor improves results.
Rapid ReadRapid Read
GLP-1 Medications Show Promise in Menopause Weight Management, But Specific Research Gaps Remain

GLP-1 Medications Show Promise in Menopause Weight Management, But Specific Research Gaps Remain

GLP-1 medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are gaining attention for their potential role in managing weight during menopause, according to Acibadem International. While no randomized trials have specifically studied GLP-1 medicines in menopausal women, subgroup data from broader trials suggest that women over 50 experience similar percentages of weight loss as younger adults. For instance, pivotal trials showed average weight loss of 15% to 21% over 68-72 weeks. An observational analysis in 2024 indicated that postmenopausal women taking semaglutide alongside hormone therapy lost more weight (16%) than those on semaglutide alone (12%). However, this finding is considered weak to moderate evidence due to the study's observational nature and small sample size. GLP-1s primarily work by reducing appetite, slowing stomach emptying, and regulating blood sugar, rather than directly affecting menopausal hormones.
Rapid ReadRapid Read
Ozempic Weight Loss Stalls: Doctors Identify Common Reasons and Solutions

Ozempic Weight Loss Stalls: Doctors Identify Common Reasons and Solutions

Many patients using Ozempic for weight loss experience stalls or find the medication 'not working,' prompting doctors to investigate several common reasons, according to Acibadem International. These include being on an early, lower dose during the step-up phase, continued high caloric intake despite reduced appetite, reaching a natural plateau after initial losses, interference from other medications or underlying health conditions (like hypothyroidism or poor sleep), or incorrect storage/injection technique. The article notes that while Ozempic is approved for type 2 diabetes, its use for weight management is often off-label, with Wegovy being the specifically approved weight-management product containing the same active molecule, semaglutide, but at higher maximum doses. True non-response, where a patient loses less than 5% of body weight after three months at the full dose, is uncommon but real.
TrendlineTrendline
Food Industry Responds to GLP-1 Medication Surge with 'GLP-1-Friendly' Food Labels

Food Industry Responds to GLP-1 Medication Surge with 'GLP-1-Friendly' Food Labels

Food Industry Responds to GLP-1 Medication Surge with 'GLP-1-Friendly' Food Labels
Rapid ReadRapid Read
GLP-1 Medications Require Special Considerations for Adults Over 65, UNC Health Geriatrician Advises

GLP-1 Medications Require Special Considerations for Adults Over 65, UNC Health Geriatrician Advises

Adults aged 65 and older considering GLP-1 medications like Ozempic and Zepbound for weight management and diabetes control need to be aware of specific considerations, according to UNC Health geriatrician John Batsis, MD. While these medications offer significant benefits in weight loss and blood sugar regulation, most initial trials were conducted on adults younger than 65, meaning there is less specific data for older populations. Dr. Batsis highlights that while the benefits of weight loss and improved blood sugar control remain, older adults face different risks. These include increased susceptibility to gastrointestinal side effects like nausea and constipation, which can lead to dehydration. Additionally, rapid weight loss in older adults can result in a more pronounced loss of muscle and bone mass, potentially increasing the risk of osteoporosis, frailty, falls, and permanent disability. He advises a 'low and slow' approach to dosing and emphasizes the importance of a balanced diet, regular exercis...
Rapid ReadRapid Read
Ozempic and GLP-1 Medications Linked to Potential Vision Side Effects, Including Rare Blindness

Ozempic and GLP-1 Medications Linked to Potential Vision Side Effects, Including Rare Blindness

Ozempic and other GLP-1 medications, while effective for managing type 2 diabetes and weight, can have various effects on eye health, according to SightMD. Some patients may experience temporary blurry vision due to fluctuations in blood sugar levels as the medication takes effect. For individuals with pre-existing diabetic retinopathy, rapid improvements in blood sugar can temporarily worsen the condition. More concerning are recent studies linking semaglutide, the active ingredient in Ozempic, to a rare condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, painless vision loss in one eye. Regulators have identified NAION as a very rare side effect, and research into this relationship is ongoing. Other potential vision changes that warrant attention include new flashes of light, sudden floaters, or shadows, which could signal a retinal emergency.
TrendlineTrendline
Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE

Eli Lilly, Novo Nordisk, and Pfizer Intensify Competition in China's Weight-Loss Drug Market at CIIE
Rapid ReadRapid Read
Sesame Care Offers Direct-to-Consumer Healthcare Marketplace with Weight Loss Program

Sesame Care Offers Direct-to-Consumer Healthcare Marketplace with Weight Loss Program

Sesame Care operates as a direct-to-consumer healthcare marketplace, connecting individuals with independent board-certified providers, including doctors and nurse practitioners. The platform aims to offer same-day care for various services, including specialist consultations and lab work, at a reduced cost, bypassing traditional insurance networks and monthly club subscriptions. A key offering from Sesame Care is a dedicated weight loss subscription program. This program encompasses initial consultations, regular follow-up appointments, and prescription management. Clinicians on the Sesame platform typically prescribe brand-name tirzepatide, which patients then pick up from their local retail pharmacy. As Sesame primarily functions as a clinician marketplace rather than a pharmacy distributor, patients are responsible for monitoring local pharmacy inventory and covering the retail cash or copay price for their prescriptions.
Rapid ReadRapid Read
FDA Issues Class II Recall for Compounded GLP-1 Medications and Peptides from Victory Medical Center Pharmacy

FDA Issues Class II Recall for Compounded GLP-1 Medications and Peptides from Victory Medical Center Pharmacy

The FDA has initiated a Class II recall for 42 compounded drug products, including GLP-1 medications and peptides, manufactured by Victory Medical Center Pharmacy in Austin, Texas. This recall, initiated on October 19, 2026, affects 5,918 vials distributed across Colorado, Florida, and Texas. The reason for the recall is a lack of processing controls at the compounding facility. These deficiencies could compromise the sterility, dosage accuracy, and stability of the medications. Among the recalled products are GLP-1 combinations containing semaglutide or tirzepatide, often used for weight loss, as well as various vitamins, minerals, a corticosteroid, and other compounds in multi-dose vials. This follows a Class I recall issued by Victory Medical Center Pharmacy in August 2026 for endotoxin-contaminated glutathione compounded multi-dose vials.
Rapid ReadRapid Read
Weight Loss, Not Mediterranean Diet Quality Alone, Linked to Reduced Inflammation in Study

Weight Loss, Not Mediterranean Diet Quality Alone, Linked to Reduced Inflammation in Study

A randomized controlled trial has indicated that weight loss achieved during intermittent fasting, rather than the quality of the Mediterranean diet alone, is associated with lower inflammation. The study explored the mechanisms behind the Mediterranean diet's health benefits, particularly its anti-inflammatory effects. Fifty-three adults with metabolic risk factors, with an average age of 55, were assigned to either a fully provided Mediterranean diet rich in extra virgin olive oil, vegetables, legumes, and whole grains, or their usual Western diet for eight weeks. During this initial phase, energy intake was adjusted to maintain stable body weight. While the Mediterranean diet reduced triglyceride levels by 22% and total and LDL cholesterol by 6% and 7% respectively, it did not significantly alter high-sensitivity C-reactive protein, a primary marker of low-grade inflammation. It was only after two fasting days per week were introduced for an additional eight weeks, leading to greater weight loss in the ...
Rapid ReadRapid Read
Ozempic and Saxenda Differ in Licensing and Dosing for Diabetes and Weight Management

Ozempic and Saxenda Differ in Licensing and Dosing for Diabetes and Weight Management

Ozempic (semaglutide) and Saxenda (liraglutide) are both GLP-1 receptor agonists used in the U.S., but they have distinct licenses and dosing schedules, according to The London Obesity Clinic. Ozempic is primarily licensed for the treatment of type 2 diabetes, while Saxenda is licensed for weight management in eligible individuals alongside dietary changes and physical activity. Although both medications work by mimicking the GLP-1 hormone to regulate appetite and blood sugar, they are not interchangeable. Ozempic is administered as a weekly injection because semaglutide remains active longer, whereas Saxenda requires daily injections. The clinic emphasizes that using Ozempic for weight management without a type 2 diabetes diagnosis is considered 'off-label' prescribing, requiring specific clinical justification and discussion. Wegovy, which also contains semaglutide, is specifically licensed for weight management.